Compare BridgeBio Pharma Inc (BBIO) vs Iris Energy Limited (IREN) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

IREN trades at $41.23, up 8.7% in the past 24 hours, with a bearish technical signal and RSI near 80 indicating potential overbought conditions. The company reported Q1 2026 revenue of $501 million and net income of $87 million, but missed EPS estimates for three consecutive quarters. Recent news highlights $2.8 billion in new AI contracts and a raised revenue target above $4 billion, signaling strong growth prospects in AI infrastructure.

The outlook is mixed: analyst consensus is bullish with a $84.43 price target, but high valuation ratios and earnings misses pose risks. Investment opportunity lies in AI contract growth, while risks include execution challenges and competitive pressures in the neocloud market.